A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Applications of Multi-omics Approaches for Exploring the Molecular Mechanism of Ovarian Carcinogenesis.Frontiers in oncology · 2021
   Review
2. Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.Cancer biology & therapy · 2020
   Article
3. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.BMC cancer · 2020
   Article
4. Genome-wide profiling of mRNA and lncRNA expression in dengue fever and dengue hemorrhagic fever.FEBS open bio · 2019
   Article
5. The Role of Pretreatment Serum Neutrophil-to-Lymphocyte Ratio in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Pilot Study.Scientific reports · 2019
   Article
6. Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis.Oncotarget · 2018
   Article
7. The prognostic values of signal transducers activators of transcription family in ovarian cancer.Bioscience reports · 2017
   Article
8. The Crosstalk between Ovarian Cancer Stem Cell Niche and the Tumor Microenvironment.Stem cells international · 2017
   Review
9. Monocyte and interferon based therapy for the treatment of ovarian cancer.Cytokine & growth factor reviews · 2016
   Article

Corrections and comments

• Erratum for
  A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.2015 · Masson, A-M M [corrected to Mes-Masson, A-M]

Authors and funding

9 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.